chemotherapy treatment for stage 1 breast cancer
Tài liệu Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study pdf
... 2.03 0 .11 11 9.62ജ50 y old 5 16 0. 31 1.00 3 .19 1. 12 11 .15 Deep vein thrombosis‡ 22 35 0.84 1. 34 1. 60 0. 91 2.86ഛ49 y old 8 11 0.78 1. 08 1. 39 0. 51 3.99ജ50 y old 14 24 0.88 1. 51 1. 71 0.85–3.58*Seven ... 0.55 0.25 1. 15Spine 31 23 1. 18 0.88 0.74 0. 41 1. 32Radius, Colles’ 23 14 0.88 0.54 0. 61 0.29 1. 23Other lower radius* 63 66 2. 41 2.54 1. 05 0.73 1. 51 Total 13 7† 11 1‡ 5.28 4.29 0. 81 0.63 1. 05ഛ49 ... 23 3 10 .11 1. 43 0 .14 0.03–0.475-y predicted breast cancer risk, %ഛ2.00 35 13 5.54 2.06 0.37 0 .18 –0.722. 01 3.00 42 29 5 .18 3. 51 0.68 0. 41 1. 11 3. 01 5.00 43 27 5.88 3.88 0.66 0.39 1. 09ജ5. 01 55...
- 18
- 645
- 0
Primary Treatment for Locally Advanced Cervical Cancer: Concurrent Platinum-based Chemotherapy and Radiation pptx
... cancer Keys, 19 99 (6) (GOG -12 3) XRT + CP XRT 9% 21% 12 % 16 % Postoperative high-risk cervical cancer Peters, 19 99 (7) (SWOG 8797) XRT + CP/5FU XRT 6% 17 % 10 % 16 % * p<0.0 01 ... 10 6 /17 3 ( 61% ) 73 /17 7 ( 41% ) 0.57 (0.42 to 0.78) 0.55 (0.40 to 0.75) Whitney, 19 99 (5) (GOG-85) 10 4 XRT + CP/5FU XRT + HU 90 /17 7 ( 51% ) 76 /19 1 (40%) 0.79 (0.62 to 0.99) Bulky stage ... cervical cancer Keys, 19 99 (6) (GOG -12 3) 36 XRT + CP + hysterectomy XRT + hysterectomy 14 4 /18 3 (79%) 11 7 /18 6 (63%) 0. 51 (0.34 to 0.75) Postoperative high-risk cervical cancer Peters, 19 99...
- 31
- 386
- 0
báo cáo hóa học: " Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and " potx
... tumours. EurJ Cancer 2004, 40(9) :13 73 -13 82.doi :10 .11 86/ 219 1- 219 X -1- 20Cite this article as: Rousseau et al.: Syndecan -1 antigen, a promisingnew target for triple-negative breast cancer immuno-PET ... MDA-MB-468 xenografttumors. EJNMMI Research 2 011 1: 20.Rousseau et al. EJNMMI Research 2 011 , 1: 20http://www.ejnmmires.com/content /1/ 1/20Page 11 of 11 37 MBq 13 1I-labeled B-B4 mAb. In the 25.9-MBq ... negative early -stage breast cancer. J ClinOncol 2006, 24(36):5652-5657. 11 . Oakman C, Viale G, Di Leo A: Management of triple negative breast cancer. Breast 2 010 , 19 (5): 312 - 21. 12 . Irvin WJ Jr,...
- 11
- 326
- 0
Báo cáo toán học: "MAINTENANCE HORMONAL TREATMENT IMPROVES PROGRESSION FREE SURVIVAL AFTER A FIRST LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST CANCER" docx
... PgR positive tumour. Key words: Breast cancer; maintenance treatment; chemotherapy; Metastatic; hormonotherapy. INTRODUCTION Breast cancer is the most common cancer among women in the USA and ... treatment improved the progression-free survival from 19 , 2 to 31, 1 months (p = 0, 022). The influence of the type of response achieved by first line chemotherapy is well established [11 ]. ... predictive factors for PFS duration after a first line chemotherapy. Table 3. Predictive factors for OS duration after a first line chemotherapy. Int. J. Med. Sci. 2008, 5 10 1patients were...
- 6
- 219
- 0
Suggested questions for stage 1
... interesting building in Guangzhou?Suggested topics in stage 2 & related questions for stage 3Category 1: Describing things (1 test item) 1. Describing a piece of equipment you often use at ... Suggestedquestionsforstage 1 Warm-up 1. Could you show me your identification card please?2. Could you tell me your full name ... popular?9. What is the difference between fresh food and canned food? 10 . What can we do to solve the problem of food shortage? 11 . What are the advantages and disadvantages of family food?2. Describing...
- 10
- 601
- 0
Guidelines for management of breast cancer ppt
... research tools. Stage grouping Stage 0: Tis, N0, M0 Stage I: T1, N0, M0 Stage IIa: T0, N1, M0 T1, N1, M0 T2, N0, M0 Stage IIb: T2, N1, M0 T3, N0, M0 Stage IIIa: T0, N2, M0 T1, N2, M0 T2, ... patients with breast cancer ultimately require treatment for advanced disease. Clinical breast cancer research has focused on effective methods to detect breast cancer at its earliest stages and ... of special problems in breast cancer 37Figure 13 . Paget’s disease of the nipple-areola complexFigure 14 . Cancer of the male breast: diagnosis Diagnosis of breast cancer 15 Prognostic factorsSeveral...
- 57
- 423
- 0
Báo cáo hóa học: "Morphologic complexity of epithelial architecture for predicting invasive breast cancer survival" ppt
... 1. 0 67.4 1. 0 1. 56 - 1. 75 14 8 56.4 1. 9 (1. 1, 3.6) 0.03 39.9 2 .1 (1. 2, 3.6) 0.008> ;1. 75 90 25.0 3.5 (1. 9, 6.4) < 0.0 01 14.2 3.6 (2 .1, 6 .1) < 0.0 01 Age≤ 55 years 78 82 .1 1.0 82 .1 1.0>55 ... 2 .1 (1. 1, 3.7) 0. 01 1.7 (1. 1, 3.0) 0.047Lymph node statusNegative 1. 0 1. 0Positive 3 .1 (1. 9, 5 .1) < 0.0 01 2.6 (1. 7, 4 .1) < 0.0 01 Estrogen-receptor statusPositive 1. 0 1. 0Negative 1. 6 ... 0.0 01 Age≤ 55 years 1. 0 1. 0>55 years 1. 8 (0.8, 4.2) 0 .14 2.7 (1. 2, 5.9) 0. 01 Size of tumour≤ 2 cm 1. 0 1. 0>2 cm 1. 0 (0.6, 1. 6) 0.96 1. 0 (0.7, 1. 6) 0.88Grade of tumour 1 & 2 1. 0 1. 03...
- 10
- 490
- 0
Báo cáo y học: "PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers"
... a potent PARP -1 inhibitor, AG143 61, on BRCA1 mutant and control cancer cells. (A) Clonogenic survival assay. Five hundred 780 (BRCA1 11 / 11 ), and 525 (BRCA1-/-), and NEU (BRCA1+/+) cells were ... human breast cancer cells using three PARP inhibitors: AG143 61, NU1025, and 3-aminobenzamide (3AB) [36]. We first tested a BRCA1 mutant ES cell line [BRCA1trEx 11/ Δ 11 that carries one BRCA1 ... breast cancer, therapeutic treatment, AG143 61 1. Introduction Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Familial breast cancer...
- 7
- 415
- 0
BREAST CANCER - TREATMENT GUIDELINES FOR PATIENTS potx
... to have breast- conserving surgery. For women whose breast cancer has spreadto other organs in the body (metastases), sys-temic treatment is the main treatment. This treatment may be chemotherapy, ... When chemotherapy is given after surgery for early stage breast cancer, it is calledadjuvant chemotherapy. Sometimes chemo-therapy is given before surgery. This is calledneoadjuvant chemotherapy. ... about your cancer or cancer treatment, please call the American Cancer Society anytime day or nightat 1- 800-ACS-2345. If a woman and her doctor choose a mas-tectomy as her breast cancer treatment, ...
- 92
- 411
- 0
Báo cáo hóa học: " A Novel Docetaxel-Loaded Poly (e-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment" pot
... 0 .17 2 9.76 65.08 -48.70 ± 3 .11 PCLPFNP 2 01. 7 ± 10 .1 0.096 10 .02 69 .10 -12 .50 ± 0.86 PCL/F68CCNP 2 81. 2 ± 5.5 0 .14 5 -35.70 ± 2.99 PCLCFNP 222.7 ± 5.4 0 .13 3 -20.50 ± 1. 34 PCL/F68Note: Group CCNP ... (2009) 4 :15 30 15 39 15 33 12 3 For example, the MCF-7 TAX30 cell viability after 1 dayincubation at the 10 lg/mL drug concentration wasdecreased from 54.37% for TaxotereÒto 49 .16 % (i.e. a 11 .42% ... 23(6), 11 91 11 98 (19 97) 21. G. Storm, S.O. Belliot, T. Daemen, D.D. Lasic, Surface modifi-cation of nanoparticles to oppose uptake by the mononuclearphagocyte system. Adv. Drug Deliv. Rev. 16 , 31 48...
- 10
- 363
- 0
báo cáo khoa học: "Surgical perspectives from a prospective, nonrandomized, multicenter study of breast conserving surgery and adjuvant electronic brachytherapy for the treatment of breast cancer" pps
... reported or not applicable 1 (2.3%) 0 (0.0%)AJCC Class: n (%)p=NSTis 12 (27.3%) 4 (19 .1% )T1a 1 (2.3%) 3 (14 .3%)T1b 8 (18 .2%) 4 (19 .1% )T1c 21 (47.7%) 8 (38 .1% )T1mic 0 (0.0%) 1 (4.8%)T2 2 (4.6%) ... Available 4 (9 .1% ) 5 (23.8%)Not reported 0 (0.0%) 1 (4.8%) Breast Cup Sizep=NSB 12 (27.3%) 7 (33.3%)C 16 (36.4%) 4 (19 .1% )D 11 (25.0%) 2 (9.5%)Not reported 5 (11 .4%) 8 (38 .1% )Lesion Location: ... Differentiated 10 (22.7%) 6 (14 %)Grade Not Available 4 (9 .1% ) 4 (9%)Minimum Distance from Balloon to Skin Surface 6 mm 5 mm Breast Cup SizeA 0 1 (2%)B 12 (27.3%) 9 ( 21% )C 16 (36.4%) 15 (35%)D+ 11 (25.0%)...
- 10
- 389
- 0
Báo cáo khoa học: "Intraoperative radiation therapy in the treatment of early-stage breast cancer utilizing xoft axxent electronic brachytherapy" ppt
... postopera-tive whole -breast radiotherapy after breast- conservingsurgery for the management of early -stage invasive breast cancer (a trial update). Amer J Surg 2007, 19 4:507- 510 . 19 . Vaidya JS, Tobias ... of intra-operative radiotherapy (IORT) in limited -stage breast can-cers that are conservatively treated. Eur J Cancer 20 01, 37 (17 ): 217 8- 218 3. 18 . Holmes DR, Baum M, Joseph D: The targit trial: ... Surgical Oncology 2009, 7:24 doi :10 .11 86 /14 77-7 819 -7-24Received: 17 December 2008Accepted: 2 March 2009This article is available from: http://www.wjso.com/content/7 /1/ 24â 2009 Dickler et al; licensee...
- 6
- 499
- 0
Báo cáo khoa học: "The "Win-Win" initiative: a global, scientifically based approach to resource sparing treatment for systemic breast cancer therapy" pdf
... palliative breast cancer treatment [10 ]. Whilean example of new applications for relatively old and lessexpensive drug is the use of Cisplatin in triple negative breast cancer patients [11 ].Generic ... Egypt, for his assistance in preparing the manuscript.References 1. Sikora K: Developing a global strategy for cancer. Eur J Cancer 19 99, 35 :18 70 -18 77.2. Stewart BW, Kleihues P: World cancer ... onlyfive percent of the global resources for cancer control [1] . Breast cancer is the most frequent cancer among females.Globally the incidence of breast cancer is increasing, andthe rate of increase...
- 5
- 265
- 0
Báo cáo khoa học: "Barriers to adequate follow-up during adjuvant therapy may be important factors in the worse outcome for Black women after breast cancer treatment" doc
... Black Other pNone, N (%) 10 1 /12 4 ( 81% ) 85/ 91 (93%) . 01 Isolated locoregional 6 /12 4 (5%) 1/ 91 (1% ) .13 Any locoregional 12 /12 4 (10 %) 1/ 91 (1% ) <. 01 Distant 18 /12 4 (15 %) 5/ 91 (5%) .03Disease-free ... 13 /12 4 (10 %) 17 / 91 (19 %)Invasive SLNB 51/ 124 ( 41% ) 34/ 91 (38%)SLNB + ALND 30 /12 4 (24%) 31/ 91 (34%)ALND 39 /12 4 (32%) 22/ 91 (24%)None 4 /12 4 (3%) 4/ 91 (4%)Invasive CT 91/ 124 (73%) 65/ 91 ( 71% )RT ... CI)Tumor size .03 1. 1 (1. 0 – 1. 2) <. 01 1.2 (1. 1 – 1. 3)Node-positive disease .04 1. 5 (1. 0 – 2.3) .02 2.2 (1. 1 – 4.5)Black race . 01 0.38 (0 .15 – 0.95) .03 0 .12 (0.02 – 1. 0)Compliance with...
- 10
- 292
- 0
Báo cáo khoa học: " Accelerated partial breast irradiation using multicatheter brachytherapy for select early-stage breast cancer: local control and toxicity" potx
... toxicityToxicity No (%)V 10 0 (cm3)P‡V 15 0 (cm3)P‡DHIP‡SkinYes* 11 (22.9) 51. 3 ± 12 .1 0.2 21 25.7 ± 6.2 0.222 0. 51 ± 0.03 0 .10 5No 37 (77 .1) 43.0 ± 18 .9 22.0 ± 8.7 0.49 ± 0.03Subcutaneous ... Harris JR: Breast relapse following primary radiation therapy for early breast cancer. I. Classification, frequency and salvage. Int J Radiat Oncol Biol Phys 19 85, 11 :12 71- 1276. 13 . Harris ... with radical mastectomy for early breast cancer. N Engl J Med 2002, 347 :12 27 -12 32.6. Morrow M: Rational local therapy for breast cancer. N Engl J Med 2002, 347 :12 70 -12 71. 7. Clarke M, Collins...
- 8
- 339
- 0
Tìm thêm: xác định các nguyên tắc biên soạn khảo sát các chuẩn giảng dạy tiếng nhật từ góc độ lí thuyết và thực tiễn khảo sát chương trình đào tạo gắn với các giáo trình cụ thể điều tra với đối tượng sinh viên học tiếng nhật không chuyên ngữ1 khảo sát các chương trình đào tạo theo những bộ giáo trình tiêu biểu nội dung cụ thể cho từng kĩ năng ở từng cấp độ phát huy những thành tựu công nghệ mới nhất được áp dụng vào công tác dạy và học ngoại ngữ mở máy động cơ lồng sóc mở máy động cơ rôto dây quấn các đặc tính của động cơ điện không đồng bộ đặc tuyến hiệu suất h fi p2 đặc tuyến mômen quay m fi p2 đặc tuyến tốc độ rôto n fi p2 đặc tuyến dòng điện stato i1 fi p2 động cơ điện không đồng bộ một pha sự cần thiết phải đầu tư xây dựng nhà máy phần 3 giới thiệu nguyên liệu từ bảng 3 1 ta thấy ngoài hai thành phần chủ yếu và chiếm tỷ lệ cao nhất là tinh bột và cacbonhydrat trong hạt gạo tẻ còn chứa đường cellulose hemicellulose chỉ tiêu chất lượng theo chất lượng phẩm chất sản phẩm khô từ gạo của bộ y tế năm 2008 chỉ tiêu chất lượng 9 tr 25